Page last checked 2026-09-07

Goal

Peptides for testosterone

Only kisspeptin-10 raised testosterone in a cited study, which used a drip into a vein in healthy men. That does not set a treatment dose.

Source for this answer

Source: Based on 4 compound guides · checked 2026-09-07

Testosterone is a steroid hormone. The four compounds below are peptides, so they do not become testosterone. People seek them to change hormone levels or ease symptoms.

These studies did not compare the peptides with prescribed testosterone. A change in a blood test is not proof that someone feels better.

At a glance

Compounds covered

FDA-approved for this goal

Being tested for this goal

Reported use only

Four compounds, and whether anyone measured the hormone

Only the kisspeptin-10 row includes a measured testosterone response in the studies cited here. Who took it and how they received it are key facts.

◆ 4 compounds coveredsources shown in each row

Compounds people take for this purpose, why they use them, what human research has measured, and where the evidence comes from.
Compound	What people take it for	What research shows	Evidence
Kisspeptin-10	Sought for testosterone support, libido and fertility.Measured in a human study	A drip into a vein for up to 22.5 hours raised testosterone in healthy men in a small study. Another study found different responses by sex and menstrual cycle phase. Women in the follicular phase showed no LH or FSH rise with intravenous or under-the-skin dosing. These results do not set a treatment dose.	limited human dataDose from a human trial · no FDA label
Sermorelin	Sold by wellness clinics for energy and body composition, and offered to men as a way around testosterone replacement or as something to run beside it.Reported use only	The cited studies did not test testosterone. The largest trial studied growth in 110 children. A 14-day study in older men used 0.5 or 1 mg twice daily; only the 1 mg group had a rise in growth hormone. The reported 200 to 300 micrograms daily is a different amount, not a dose shown to raise testosterone.	limited human dataDose from a human trial · no FDA label
TesamorelinEgrifta SV, Egrifta WR	Sought to raise testosterone based on its effects on growth hormone.Reported use only	Its approved use is excess abdominal fat in adults with HIV-related lipodystrophy. Egrifta SV uses 1.4 mg once daily; Egrifta WR uses a different dose and is not substitutable. These labels do not show a testosterone-treatment schedule.	FDA labelDose from the FDA-approved label
BPC-157	Bought for tendon, muscle and gut complaints, and asked about both as a testosterone raiser and as something to run beside one.Reported use only	The small human reports did not test testosterone. They tracked knee pain, bladder symptoms or short-term effects of a drip into a vein. None used an injection under the skin. A review gives a reported daily range of 200–500 micrograms, drawn from informal scaling of rodent doses.	no human dose shown to workDose reported in the literature only

1 rests on a human study that measured something in this goal. 3 rest on reported use alone, with no study behind them.

The kisspeptin study was a hormone experiment

Healthy men received kisspeptin-10 through a vein for up to 22.5 hours. Their testosterone rose during the study. The groups were small and the dose depended on body weight. It did not test a treatment for low testosterone.

A separate study found that sex and cycle phase affected the hormone response. Women in the follicular phase, early in the cycle, had no rise in LH or FSH after doses into a vein or under the skin. The route alone cannot explain how these groups differed.

FDA’s compounding committee reviewed kisspeptin-10 for low hormone function in men in October 2024. A review is not an approval and does not set a treatment dose.

A hormone change is not a replacement-treatment result

The studies do not show that sermorelin, tesamorelin or BPC-157 raise or lower testosterone. Other hormone changes cannot fill in that gap.

The kisspeptin-10 findings come from small, short studies in healthy volunteers. They do not show whether people with low testosterone feel better or benefit from long-term use.

Reported amounts for other uses remain separate: 200 to 300 micrograms daily for sermorelin and 200 to 500 for BPC-157. These are amounts reported in use, not established testosterone-treatment doses.

Where to go next

Which purposes have evidence behind them

4 pairings have an FDA-approved product, 2 have an approval outside the U.S., and 6 are being tested in trials.

Every compound sold for skin

3 compounds are sold or prescribed for skin; the comparison shows what has actually been studied.

Which weight loss claims have a trial

What this comparison still cannot tell one person — see which popular claims still have no human evidence.

How Kisspeptin-10 differs from the rest of its class

No published human dosing schedule was found for Kisspeptin-10.

BPC-157 research, dosing, and approval status

No regulator has approved BPC-157; the guide separates human studies from reported use.

How sermorelin differs from the rest of its class

No published human dosing schedule was found for sermorelin.

The molecule behind Egrifta SV and Egrifta WR

No published half-life figure was found for tesamorelin.

Where the sleep evidence stops

Compare all 5 compounds associated with sleep, with a source for every supported claim.

Every purpose covered this way is listed on the index of goals people buy peptides for.

Questions readers ask

Does CJC Ipamorelin affect testosterone?

The studies cited here do not measure testosterone after using the pair. The separate records cover growth hormone, IGF-I or bowel function after surgery.

Does TB500 affect testosterone?

The TB-500 record does not establish an effect on testosterone. FDA reports that it has not identified human exposure data for the fragment it names TB-500.

Does CJC-1295 suppress testosterone?

The cited CJC-1295 studies measured growth hormone and IGF-I, not a testosterone-suppression outcome. They do not establish whether it raises or lowers testosterone.

Does CJC-1295 Ipamorelin decrease testosterone?

No study cited here answers that question for the combination. Results for growth hormone or IGF-I cannot be used as testosterone results.

Does CJC affect testosterone?

The CJC-1295 studies cited here do not establish a testosterone effect. A hormone that was not reported as an outcome should be treated as unknown, not unchanged.

Are peptides better than testosterone?

These sources do not compare the peptides with testosterone replacement. Kisspeptin-10 studies measured testosterone as an outcome; they did not test it against testosterone as a treatment.

Is it better to take peptides or testosterone?

The studies here cannot answer that personal treatment question. They do not compare peptide treatment with testosterone replacement or establish that the two serve the same purpose.

Does IGF-1 increase testosterone?

This site’s IGF-1 LR3 record does not include a human testosterone result. IGF-1 LR3 is a modified form; its cell and animal findings should not be generalized to all IGF-1 products.

How much can kisspeptin raise testosterone?

One small study reported an increase during an intravenous infusion in healthy men. Groups included four to six people. It does not provide a reliable estimate for another person or dosing schedule.

Will kisspeptin raise testosterone?

Kisspeptin-10 raised testosterone during a small infusion study in healthy men. That does not establish the response to an injection under the skin or treatment of testosterone deficiency.

8primary sources, each with the day we read it — open the documents used on this page